Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075554 | 0.99 | HRH4 (0.56) | HRH4SMN1; SMN2ALDH1A1RAB9AEGFR | |
| SCHEMBL2072889 | 0.83 | HRH4 (0.56) | HRH4SMN1; SMN2ALDH1A1RAB9AEGFR | |
| SCHEMBL2075546 | 0.83 | HRH4 (0.52) | HRH4SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL2075148 | 0.83 | HRH4 (0.52) | HRH4SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL2075159 | 0.83 | HRH4 (0.55) | HRH4SMN1; SMN2ALDH1A1RAB9AEGFR | |
| SCHEMBL2073950 | 0.82 | HRH4 (0.57) | HRH4SMN1; SMN2ALDH1A1RAB9AEGFR | |
| SCHEMBL4170894 | 0.82 | HRH3 (0.44) | HRH4SMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL2074070 | 0.82 | HRH4 (0.56) | HRH4SMN1; SMN2ALDH1A1RAB9AEGFR | |
| SCHEMBL2074954 | 0.81 | HRH4 (0.55) | HRH4SMN1; SMN2ALDH1A1RAB9AEGFR | |
| SCHEMBL2074480 | 0.81 | HRH4 (0.55) | HRH4SMN1; SMN2ALDH1A1RAB9AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902184-B2 | Piperazinyl pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| CN-101448820-A | Piperidinyl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-2032554-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007137955-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HRH2, P2RX5, P2RX3 | HRH4 4/4885SMN1; SMN2 4105/4885ALDH1A1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.